Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced its continued ...
The revolutionary BiVACOR heart device was moved to Phase 2 of FDA trials after success in five human patients.
GlobalData on MSN13h
Phoenix Molecular kicks off Phase II part of breast cancer combo trialThe Phase II portion is seeking to establish safety and efficacy of the company’s HER2 breast cancer therapy in combination ...
GlobalData on MSN9h
J&J’s fully subcutaneous Tremfya shows 27.6% clinical remission in UCTremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate ...
Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...
7hon MSN
A promising new mRNA-based vaccine for pancreatic cancer has shown potential in reducing the recurrence of the disease post-surgery. MSK's phase 1 cli ...
IFLScience on MSN9h
Inhalable Cystic Fibrosis Gene Therapy 24 Years In The Making Enters Clinical TrialsA new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey ...
Q4 2024 Earnings Call Transcript February 20, 2025 Prothena Corporation plc misses on earnings expectations. Reported EPS is ...
NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback